Please login to the form below

Not currently logged in


This page shows the latest KEYNOTE-177 news and features for those working in and with pharma, biotech and healthcare.

NICE recommends Keytruda for colorectal cancer patients with rare mutations

NICE recommends Keytruda for colorectal cancer patients with rare mutations

In the phase 3 KEYNOTE-177 trial, Keytruda was found to slow or halt progression of metastatic MSI-H/dMMR colorectal cancers for a median of 16.5 months versus ... Merck &Co added in its own statement that the KEYNOTE-177 trial is still ongoing to assess

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Madmicrobe Studios - Medical Animation

MadMicrobe is an award-winning team of certified medical illustrators creating animations that engage your audience with immersive experiences that bring...

Latest intelligence

The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
Report: Omnichannel advice for the life science industry
In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...